265 related articles for article (PubMed ID: 21970698)
21. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia.
Berger A; Sadosky A; Dukes EM; Edelsberg J; Zlateva G; Oster G
Am J Manag Care; 2010 May; 16(5 Suppl):S126-37. PubMed ID: 20586521
[TBL] [Abstract][Full Text] [Related]
22. Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs. standard of care.
Kleinman NL; Sanchez RJ; Lynch WD; Cappelleri JC; Beren IA; Joshi AV
Pain Pract; 2011; 11(6):540-51. PubMed ID: 21392253
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine.
Margolis J; Cao Z; Fowler R; Harnett J; Sanchez RJ; Mardekian J; Silverman SL
J Med Econ; 2010; 13(4):738-47. PubMed ID: 21091395
[TBL] [Abstract][Full Text] [Related]
24. Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact.
Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
Pain Med; 2014 Aug; 15(8):1282-93. PubMed ID: 24401017
[TBL] [Abstract][Full Text] [Related]
25. Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin.
Cappelleri JC; Bushmakin AG; Zlateva G; Chandran A
J Med Econ; 2013; 16(1):55-61. PubMed ID: 22954060
[TBL] [Abstract][Full Text] [Related]
26. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study.
Roth T; Lankford DA; Bhadra P; Whalen E; Resnick EM
Arthritis Care Res (Hoboken); 2012 Apr; 64(4):597-606. PubMed ID: 22232085
[TBL] [Abstract][Full Text] [Related]
27. Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators.
Marlow NM; Simpson KN; Vaughn IA; Jo A; Zoller JS; Short EB
Pain Pract; 2018 Feb; 18(2):154-169. PubMed ID: 28419725
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin.
Kim SC; Landon JE; Solomon DH
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1813-9. PubMed ID: 23861291
[TBL] [Abstract][Full Text] [Related]
29. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia.
White LA; Robinson RL; Yu AP; Kaltenboeck A; Samuels S; Mallett D; Birnbaum HG
J Pain; 2009 Sep; 10(9):976-83. PubMed ID: 19556168
[TBL] [Abstract][Full Text] [Related]
30. Use of pregabalin in patients with painful neuropathic disorders under the care of general practitioners in the U.K.
Berger A; Sadosky A; Dukes E; Edelsberg J; Oster G
Pain Pract; 2009; 9(1):18-34. PubMed ID: 19019054
[TBL] [Abstract][Full Text] [Related]
31. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
Kirson NY; Ivanova JI; Birnbaum HG; Wei R; Kantor E; Puenpatom RA; Ben-Joseph RH; Summers KH
J Med Econ; 2010; 13(3):482-91. PubMed ID: 20684669
[TBL] [Abstract][Full Text] [Related]
32. Predictors of pain medication selection among patients diagnosed with fibromyalgia.
Boulanger L; Wu N; Chen SY; Nagar S; Fraser K; Bernauer MJ; Zhao Z; Zhao Y
Pain Pract; 2012 Apr; 12(4):266-75. PubMed ID: 21899718
[TBL] [Abstract][Full Text] [Related]
33. The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings.
Gore M; Sadosky A; Stacey BR; Tai KS; Leslie D
Spine (Phila Pa 1976); 2012 May; 37(11):E668-77. PubMed ID: 22146287
[TBL] [Abstract][Full Text] [Related]
34. Fibromyalgia: poorly understood; treatments are disappointing.
Prescrire Int; 2009 Aug; 18(102):169-73. PubMed ID: 19746561
[TBL] [Abstract][Full Text] [Related]
35. Long-term maintenance of response across multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin.
Pauer L; Atkinson G; Murphy TK; Petersel D; Zeiher B
Clin J Pain; 2012 Sep; 28(7):609-14. PubMed ID: 22688598
[TBL] [Abstract][Full Text] [Related]
36. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
[TBL] [Abstract][Full Text] [Related]
37. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
[TBL] [Abstract][Full Text] [Related]
38. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia.
Pauer L; Winkelmann A; Arsenault P; Jespersen A; Whelan L; Atkinson G; Leon T; Zeiher B;
J Rheumatol; 2011 Dec; 38(12):2643-52. PubMed ID: 21965636
[TBL] [Abstract][Full Text] [Related]
39. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans.
Margolis JM; Cao Z; Onukwugha E; Sanchez RJ; Alvir J; Joshi AV; Mullins CD
Am J Manag Care; 2010 Jun; 16(6):447-56. PubMed ID: 20560688
[TBL] [Abstract][Full Text] [Related]
40. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.
Arnold LM; Russell IJ; Diri EW; Duan WR; Young JP; Sharma U; Martin SA; Barrett JA; Haig G
J Pain; 2008 Sep; 9(9):792-805. PubMed ID: 18524684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
